Beyond mere DNA damage: Recent progress in platinum(IV) anticancer complexes containing multi-functional axial ligands

Curr Opin Chem Biol. 2023 Jun:74:102303. doi: 10.1016/j.cbpa.2023.102303. Epub 2023 Apr 17.

Abstract

The clinical application of Pt-based anticancer drugs has inspired the development of novel chemotherapeutic metallodrugs with improved efficacies. Pt(IV) prodrugs are one of the most promising successors of Pt(II) drugs and have displayed great anticancer performance. In particular, judicious modification of axial ligands endows Pt(IV) complexes with unique properties that enable them to overcome the limitations of conventional Pt(II) drugs. Herein, we summarize recent developments in Pt(IV) anticancer complexes, with a focus on their axial functionalization with other anticancer agents, immunotherapeutic agents, photosensitive ligands, peptides, and theranostic agents. We hope that this concise view of recently reported Pt(IV) coordination complexes will help researchers to design next-generation multi-functional anticancer agents based on a comprehensive Pt(IV) platform.

Keywords: Anticancer agent; Chemo-immunotherapy; Chemotherapy; Platinum drug; Pt(IV) prodrug.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / chemistry
  • Antineoplastic Agents* / pharmacology
  • Cell Line, Tumor
  • Coordination Complexes* / chemistry
  • Coordination Complexes* / pharmacology
  • DNA Damage
  • Ligands
  • Platinum / chemistry
  • Prodrugs* / chemistry
  • Prodrugs* / pharmacology

Substances

  • Platinum
  • Antineoplastic Agents
  • Prodrugs
  • Coordination Complexes
  • Ligands